Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.

"the clinical relevance of the gene expression changes due to nn1177 in nash in our mouse model was investigated using two publicly available datasets of human nash liver samples obtained from the gene expression omnibus (geo) [ ]: gse162694 (srp295965) [ ] and gse130970 (srp19735) [ ].; = p < 0 05 na = not applicable nt = not tested ns = not significant 2 11 the mouse data generated in this paper is available on the online repository gene expression omnibus (geo) under the accession gse220519 ."

"the code used to generate the results is available in the github repository https://github com/novonordisk-research/nn1177_liver_rnaseq 3 male c57bl/6 mice were fed a fructose and high fat rich diet for 36 weeks to induce the nash phenotype (dio-nash) and animals with steatosis score of minimum 2 and fibrosis score of minimum 1 were randomized based on baseline collagen 1a1 area% to receive either once daily s c administration of vehicle (nash vehicle) or three different doses of nn1177 (0 75 nmol/kg 2 nmol/kg or 4 nmol/kg) for 8 weeks."

"Declaration of competing interest Thomas Monfeuga, Jenny Norlin, Anne Bugge, Elisabeth D. Gaalsgaard, Cesar A. Prada-Medina, Markus Latta, Sanne S. Veidal and Dorte Holst are employees of Novo Nordisk A/S and shareholders in Novo Nordisk A/S. Pia S. Petersen is currently employee at Ascendis Pharma A/S and Michael Feigh is employee at Gubra A/S."